Ibritumomab tiuxetan (Zevalin, Spectrum) has been approved for patients with previously untreated follicular non-Hodgkin’s lymphoma (NHL) who have achieved a partial or complete response to first-line chemotherapy. This recent indication supplements the drug’s 2002 approval as a therapy for patients with relapsed or refractory low-grade or follicular B-cell NHL. This agent is a CD20-directed radiotherapeutic antibody.

Source: FDA, The Medical News, September 5, 2009

Random Posts:

• First Angiogenesis Inhibitor for Colorectal Cancer
• FDA Clears Generic Paxil
• Warning for Rotavirus Vaccine
• Synthetic Cholesterol Removes Plaque from Coronary Arteries
• Gabapentin for Hot Flashes